TrialBlood2026
A phase 3 study of intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.
Hartmut Döhner et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papertrialcites it